Sotagliflozin with insulin for treating type 1 diabetes - guidance (TA622)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
12 February 2020

Abstract

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Therefore the period of time the NHS has to comply with these recommendations has been extended (see the section on implementation).

Is this guidance up to date?

Next review: 2023

Guidance development process

How we develop NICE technology appraisal guidance